STRATEC SE : Q1 review - Solid start to 2022, as expected no guidance upgrade
>Q1 review : better top and bottom line, except for EPS - Stratec’s Q1 revenues of € 75.4m (+4.7% y-o-y) were driven by organic growth of 1.8% and forex tailwind of 290bps. Our forecast stood at € 72m and we expected an organic decline of 2.0%. Growth was driven by strong business with service parts and consumables and higher sales with development and services. System business decreased in line with expectations following a very strong demand over the last two years....STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.